LncRNA UCA1 Induces Acquired Resistance to Gefitinib by Epigenetically Silencing CDKN1A Expression in Non-small-Cell Lung Cancer

Lung cancer is the most common cancer globally and is associated with high morbidity and mortality. Gefitinib has been widely used for treating advanced non-small-cell lung cancer (NSCLC). However, acquired resistance usually develops, although we still know little about the mechanism underlying thi...

全面介绍

书目详细资料

Principais autores:	Tianwei Xu, Shuai Yan, Mengwei Wang, Lihua Jiang, Pei Ma, Binbin Lu, Qinnan Chen, Chenchen Wei, Zhaoxia Wang
格式:	Artigo
语言:	Inglês
出版:	Frontiers Media S.A. 2020-05-01
丛编:	Frontiers in Oncology
主题:	lncRNA UCA1 CDKN1A NSCLC gefitinib resistance
在线阅读:	https://www.frontiersin.org/article/10.3389/fonc.2020.00656/full
标签:	添加标签 没有标签, 成为第一个标记此记录!